Providence Swedish Inflammatory Bowel Disease Conference 2024

Description

+ Include: 16 Videos (.mp4) + 11 Audios (.mp3) + 11 Subtitles (.vtt) + 10 PDFs, size: 12.42 GB

+ Target Audience: gastroenterologists and surgeons

+ Sample video: contact me for sample video

+ Information:

1. Overview

The Providence Swedish Inflammatory Bowel Disease Conference 2024 provides a cutting-edge review of IBD management, focusing on optimizing biologic and small molecule therapies. The course explores emerging treatments, surgical interventions, and strategies for achieving mucosal healing in complex Crohn’s and colitis cases.

Course Date: June 1, 2024

2. Learning Objectives

• Interpret data from head-to-head trials to select optimal therapies for IBD patients.

• Implement strategies for optimizing biologics and small molecules, including combination therapies for refractory disease.

• Evaluate the clinical impact of mucosal healing and the safety of biosimilars in practice.

• Discuss the role of surgery as a first-line therapy for Crohn’s disease and best practices for colorectal neoplasia surveillance.

• Integrate clinical pharmacists into the multidisciplinary care team to enhance patient outcomes.

3. Target Audience

Best for gastroenterologists and surgeons who want updates on biologic optimization, refractory IBD management, and emerging therapies.

4. Topics

1. Interpretation and Clinical Implications of Head-to-head Trials in IBD

2. How I Optimize Biologic Therapies in IBD

3. How I Optimize Biologic Therapies in IBD Q&A

4. How I Optimize Small Molecules in IBD

5. Combining Advanced Therapies for Refractory IBD – Ready for 2024

6. New and Emerging Therapies for IBD in 2024

7. Seeing is Believing – The Impact of Mucosal Healing in IBD

8. The Knife is Always Sharp – Surgery as a First Line Therapy in Crohn’s Disease

9. Colorectal Neoplasia Surveillance in IBD

10. Working with a Clinical Pharmacist in IBD

11. Is There Anyone Still afraid of Biosimilars